Literature DB >> 19877226

Patterns of recurrence and survival of head and neck adenoid cystic carcinoma after definitive resection.

Agnes Oplatek1, Enver Ozer, Amit Agrawal, Sumit Bapna, David E Schuller.   

Abstract

OBJECTIVES/HYPOTHESIS: To determine factors impacting recurrence and long-term survival of adenoid cystic carcinoma (ACC) of the head and neck after definitive resection. STUDY
DESIGN: Retrospective cohort study at an academic tertiary care hospital.
METHODS: Patients with ACC of the head and neck treated at our institution were reviewed. Those not receiving surgery, or with metastatic disease were excluded. Clinicopathological data on each patient was collected.
RESULTS: Of 113 patients identified with ACC, 99 were studied. The overall median survival for the cohort was 71 months (mean +/- standard deviation, 94 +/- 79 months). American Joint Committee on Cancer (AJCC) tumor stage and N stage were independent predictors of survival on multivariate analysis. Mean overall survival (P = .001) and time to recurrence (P = .006) were lower for patients with cervical lymph node positive disease (N+). Tumors in major salivary glands were associated with longer survival (P = .027). The overall recurrence rate was 53%, with a mean time to recurrence of 63 +/- 64 months. The presence of lymphovascular invasion predicted recurrence on multivariate analysis (P = .002), with advanced tumor stage predicting early (<or=36 months) recurrence (P = .013). Among the 57 patients who received adjuvant radiation therapy, there was no difference in survival, rate of recurrence, or time to recurrence, when compared to patients treated with surgery alone.
CONCLUSIONS: Clinicopathological variables including AJCC tumor stage, tumor site, presence of N+ disease, and lymphovascular invasion may be used as prognostic factors in predicting survival and recurrence after a definitive resection of ACC of the head and neck.

Entities:  

Mesh:

Year:  2010        PMID: 19877226     DOI: 10.1002/lary.20684

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  26 in total

1.  Predictors of Outcome in Adenoid Cystic Carcinoma of Salivary Glands: A Clinicopathologic Study With Correlation Between MYB Fusion and Protein Expression.

Authors:  Bin Xu; Esther Drill; Allen Ho; Alan Ho; Lara Dunn; Carlos Nicolas Prieto-Granada; Timothy Chan; Ian Ganly; Ronald Ghossein; Nora Katabi
Journal:  Am J Surg Pathol       Date:  2017-10       Impact factor: 6.394

2.  MYB fusions and CD markers as tools for authentication and purification of cancer stem cells from salivary adenoid cystic carcinoma.

Authors:  Alex Panaccione; Yi Zhang; Molly Ryan; Christopher A Moskaluk; Karen S Anderson; Wendell G Yarbrough; Sergey V Ivanov
Journal:  Stem Cell Res       Date:  2017-05-05       Impact factor: 2.020

3.  Disparities in Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas.

Authors:  Richard J Cassidy; Jeffrey M Switchenko; Mark W El-Deiry; Ryan H Belcher; Jim Zhong; Conor E Steuer; Nabil F Saba; Mark W McDonald; David S Yu; Theresa W Gillespie; Jonathan J Beitler
Journal:  Laryngoscope       Date:  2018-09-08       Impact factor: 3.325

4.  MicroRNA dysregulation in adenoid cystic carcinoma of the salivary gland in relation to prognosis and gene fusion status: a cohort study.

Authors:  Simon Andreasen; Qihua Tan; Tina Klitmøller Agander; Thomas V O Hansen; Petr Steiner; Kristine Bjørndal; Estrid Høgdall; Stine Rosenkilde Larsen; Daiva Erentaite; Caroline Holkmann Olsen; Benedicte Parm Ulhøi; Steffen Heegaard; Irene Wessel; Preben Homøe
Journal:  Virchows Arch       Date:  2018-08-01       Impact factor: 4.064

5.  Adenoid cystic carcinoma of the upper airway mimicking a thyroid tumor: A case report.

Authors:  Turki Aldrees; Abdullah Alanazi; Hanadi A Fatani; Abdulhadi Samman; Saleh F Aldhahri
Journal:  Mol Clin Oncol       Date:  2016-06-13

6.  Clinicopathological review and survival characteristics of adenoid cystic carcinoma.

Authors:  Fariba Binesh; Ali Akhavan; Omid Masumi; Abbas Mirvakili; Nasim Behniafard
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-08-05

Review 7.  Cervical lymph node metastasis in adenoid cystic carcinoma of oral cavity and oropharynx: A collective international review.

Authors:  Carlos Suárez; Leon Barnes; Carl E Silver; Juan P Rodrigo; Jatin P Shah; Asterios Triantafyllou; Alessandra Rinaldo; Antonio Cardesa; Karen T Pitman; Luiz P Kowalski; K Thomas Robbins; Henrik Hellquist; Jesus E Medina; Remco de Bree; Robert P Takes; Andrés Coca-Pelaz; Patrick J Bradley; Douglas R Gnepp; Afshin Teymoortash; Primož Strojan; William M Mendenhall; Jean Anderson Eloy; Justin A Bishop; Kenneth O Devaney; Lester D R Thompson; Marc Hamoir; Pieter J Slootweg; Vincent Vander Poorten; Michelle D Williams; Bruce M Wenig; Alena Skálová; Alfio Ferlito
Journal:  Auris Nasus Larynx       Date:  2016-03-24       Impact factor: 1.863

8.  MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma.

Authors:  Eleni M Rettig; Marietta Tan; Shizhang Ling; Raluca Yonescu; Justin A Bishop; Carole Fakhry; Patrick K Ha
Journal:  Laryngoscope       Date:  2015-05-11       Impact factor: 3.325

9.  Clinical Outcomes and Prognostic Factors of Adenoid Cystic Carcinoma of the Head and Neck.

Authors:  Samuel Jang; Priyesh N Patel; Randall J Kimple; Timothy M McCulloch
Journal:  Anticancer Res       Date:  2017-06       Impact factor: 2.480

10.  Nomograms for predicting survival and recurrence in patients with adenoid cystic carcinoma. An international collaborative study.

Authors:  Ian Ganly; Moran Amit; Lei Kou; Frank L Palmer; Jocelyn Migliacci; Nora Katabi; Changhong Yu; Michael W Kattan; Yoav Binenbaum; Kanika Sharma; Ramer Naomi; Agbetoba Abib; Brett Miles; Xinjie Yang; Delin Lei; Kristine Bjoerndal; Christian Godballe; Thomas Mücke; Klaus-Dietrich Wolff; Dan Fliss; André M Eckardt; Copelli Chiara; Enrico Sesenna; Safina Ali; Lukas Czerwonka; David P Goldstein; Ziv Gil; Snehal G Patel
Journal:  Eur J Cancer       Date:  2015-11-19       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.